PRO114 EQ-5D UTILITY ESTIMATES FOR PATIENTS WITH SYSTEMIC SCLEROSIS (SSC). INSIGHTS FROM THE FOCUSSCED PHASE III EFFICAY AND SAFETY STUDY OF TOCILIZUMAB.
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.2444
https://www.valueinhealthjournal.com/article/S1098-3015(19)34822-3/fulltext
Title :
PRO114 EQ-5D UTILITY ESTIMATES FOR PATIENTS WITH SYSTEMIC SCLEROSIS (SSC). INSIGHTS FROM THE FOCUSSCED PHASE III EFFICAY AND SAFETY STUDY OF TOCILIZUMAB.
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)34822-3&doi=10.1016/j.jval.2019.09.2444
First page :
Section Title :
Open access? :
No
Section Order :
12138